



UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231 www.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/873,075

06/01/2001

Allan Svendsen

10038.200-US

**CONFIRMATION NO. 4049** 

FORMALITIES LETTER

\*OC000000007145782\*

25908 NOVOZYMES NORTH AMERICA, INC. C/O NOVO NORDISK OF NORTH AMERICA, INC. 405 LEXINGTON AVENUE, SUITE 6400 NEW YORK, NY 10174

Date Mailed: 12/03/2001

# NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov


A copy of this notice <u>MUST</u> be returned with the reply.

BB

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE





PATENT

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Svendsen et al.

Confirmation No: 4049

Serial No.: 09/873,075

Group Art Unit: 1633

Filed: June 1, 2001

Examiner: To Be Assigned

For: Cutinase Variants

## **CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Box Sequence U.S. Patent and Trademark Office P.O. Box 2327 Arlington, VA 22202

Sir:

I hereby certify that the attached correspondence comprising:

- 1. Response to Notice to Comply with Sequence Rules
- 2. Sequence Listing
- 3. Copy of Notice to Comply with Sequence Rules
- 4. Disk Containing Sequence Listing

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Box Sequence U.S. Patent and Trademark Office P.O. Box 2327 Arlington, VA 22202

on February 4, 2002.

Julie Tabarovsky (name of person mailing paper)

signature of person mailing paper

ttorney Docket No.: 10038.200-US

PATENT

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Svendsen et al.

Confirmation No: 4049

Serial No.: 09/873,075

Group Art Unit: 1633

Filed: June 1, 2001

Examiner: To Be Assigned

For: Cutinase Variants

## RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE REQUIREMENTS

**Box Sequence** U.S. Patent and Trademark Office P.O. Box 2327 Arlington, VA 22202

Sir:

This paper is in response to the Notice to Comply with Sequence Requirements dated December 3, 2001. The Notice stated that the computer readable form that was filed with the application was damaged and/or unreadable.

Applicants therefore enclose another computer readable form of the Sequence Listing. The content of the paper copy that was filed with the application and of the enclosed computer readable form is the same. This submission contains no new matter.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: February 4, 2002

Jason I. Garbell, Reg. No. 44,116 Novozymes North America, Inc. 405 Lexington Avenue, Suite 6400

New York, NY 10174-6401

(212) 867-0123